Inhalable point-of-care urinary diagnostic platform
Files
Published version
Date
2024-01-05
Version
Published version
OA Version
Citation
Q. Zhong, E.K.W. Tan, C. Martin-Alonso, T. Parisi, L. Hao, J.D. Kirkpatrick, T. Fadel, H.E. Fleming, T. Jacks, S.N. Bhatia. 2024. "Inhalable point-of-care urinary diagnostic platform." Science Advances, Volume 10, Issue 1, pp.eadj9591-. https://doi.org/10.1126/sciadv.adj9591
Abstract
Although low-dose computed tomography screening improves lung cancer survival in at-risk groups, inequality remains in lung cancer diagnosis due to limited access to and high costs of medical imaging infrastructure. We designed a needleless and imaging-free platform, termed PATROL (point-of-care aerosolizable nanosensors with tumor-responsive oligonucleotide barcodes), to reduce resource disparities for early detection of lung cancer. PATROL formulates a set of DNA-barcoded, activity-based nanosensors (ABNs) into an inhalable format. Lung cancer-associated proteases selectively cleave the ABNs, releasing synthetic DNA reporters that are eventually excreted via the urine. The urinary signatures of barcoded nanosensors are quantified within 20 min at room temperature using a multiplexable paper-based lateral flow assay. PATROL detects early-stage tumors in an autochthonous lung adenocarcinoma mouse model with high sensitivity and specificity. Tailoring the library of ABNs may enable not only the modular PATROL platform to lower the resource threshold for lung cancer early detection tools but also the rapid detection of chronic pulmonary disorders and infections.
Description
License
© 2024 the Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. no claim to original U.S. Government Works. distributed under a creative commons Attribution license 4.0 (CC BY).